WHITEHAWK THERAPEUTICS, INC. Deferred Tax Liabilities, Gross
WHITEHAWK THERAPEUTICS, INC. (WHWK) had Deferred Tax Liabilities, Gross of $115.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-12
- 2025-12-31: Deferred Tax Liabilities, Gross $115.00K.
- 2024-12-31: Deferred Tax Liabilities, Gross $390.00K.
- 2023-12-31: Deferred Tax Liabilities, Gross $560.00K.
- 2022-12-31: Deferred Tax Liabilities, Gross $586.00K.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $115.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | $390.00K 10-K · filed 2026-03-12 | |
| 2023-12-31 | $560.00K 10-K · filed 2025-03-28 | |
| 2022-12-31 | $586.00K 10-K · filed 2024-03-13 | |
| 2021-12-31 | $764.00K 10-K · filed 2023-03-29 | |
| 2020-12-31 | $19.00K 10-K · filed 2022-03-17 | $31.79K 10-K · filed 2021-03-11 |
| 2019-12-31 | $61.01K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $8.39K 10-K · filed 2020-03-16 | |
| 2017-12-31 | $3.61K 10-K · filed 2019-03-07 | |
| 2016-12-31 | $8.43K 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |